Muckle-Wells Syndrome - 14 Studies Found
Completed |
: Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome : Muckle Wells Syndrome : 2007-04-25 :
|
Completed |
: Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) :
: 2010-01-07 : Drug: rilonacept 160mg of rilonacept 1x/week Other N |
Withdrawn |
: A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease :
: Drug: Canakinumab (ACZ885) 6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with |
Completed |
: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease :
: Drug: ACZ885 |
Completed |
: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase :
: Drug: canakinumab canakinumab |
Completed |
: The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy : Dental Pulp Exposure : 2005-09-13 :
|
Active, not recruiting |
: Continued Access to PREVAIL (CAP2) : Atrial Fibrillation : 2012-11-06 : Device: WATCHMAN LAA Closure Technology |
Completed |
: Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) :
|
Completed |
: Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms : NALP3 Mutation : 2007-06-18 : Drug: canakinumab |